Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTX-TIC
- Development stage
- Unknown
- Lead developer
- Ocular Therapeutix
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
OTX-TIC (AM008) is a long-acting, bioresorbable intracameral implant containing travoprost, a prostaglandin F2α analog. Developed by Ocular Therapeutix and licensed to AffaMed Therapeutics for Greater China and other Asian markets, it utilizes a proprietary hydrogel-based delivery technology. The implant is designed to be injected into the anterior chamber of the eye to provide sustained reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension, potentially replacing the need for daily topical eye drops and improving patient adherence.
- Other names
- travoprost intracameral implant
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on OTX-TIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTX-TIC.